Seracare/Seraseq™ Cardiomyopathy Reference Material/07400021/1 × 200 µL

Seraseq Cardiomyopathy Reference Material addresses the lack of multiplexed reference materials with an expert-designed product(1) for targeted NGS assays focused on hypertrophic cardiomyopathy (HCM). This unique product combines ten actionable HCM mutations in a well-characterized genomic background at a 50% target allele frequency that can be used for assay development, analytical validation, and to support laboratory quality assurance. 

Seraseq Cardiomyopathy Reference Material includes:

• Ten variants considered pathogenic or likely pathogenic for HCM
• Mutation targets precisely quantitated with digital PCR
• Well-characterized GM24385 human genomic DNA as background ‘wild-type’ material
• Formulated at a 50 ng/µL concentration in a fill volume of 200 µL
• Manufactured in cGMP compliant, ISO 9001 and ISO 13485 certified facilities
  
  

Mutations included in the Seraseq Cardiomyopathy Reference Material

Expert-design supports targeted NGS assays

 
References

1. Emily M Kudalkar^A*, Naif AM Almontarishi^A,B,C*,Catherine Huang ^D, Bharathi Anekella ^D, Mark Bowser^A, Elizabeth Hynes^A, Russell Garlick ^D, Birgit H. Funke^A,B. Multiplexed reference materials as controls for diagnostic next generation sequencing – a pilot investigating applications for hypertrophic cardiomyopathy, The Journal of Molecular Diagnostics (in press).

^A Laboratory for Molecular Medicine (LMM), Partners Healthcare Personalized Medicine; Cambridge, MA, ^B Department of Pathology/MGH, Harvard Medical School, Boston, MA, ^C Center for Genetics and Inherited Diseases; Taibah University, Almadinah Almuwarah, KSA,^D SeraCare Life Sciences Inc, Milford, MA.

*Contributed equally to this work

For research use only. Not for use in diagnostic procedures.